{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:06:19Z","timestamp":1762509979966,"version":"build-2065373602"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mirabegron is a beta 3-adrenoceptor agonist that can help with incontinence, dysuria, and bladder overactivity. It alleviates the symptoms of prostate enlargement and urinary tract infections (UTIs) in the elderly. We aimed to explore Mirabegron\u2019s antimicrobial and immune-boosting properties, trying to benefit people suffering from urinary tract infections and having an overactive bladder. Mirabegron\u2019s putative antibacterial activity was investigated using the well diffusion method (In Vitro). Infected rats were treated with mirabegron (10\u00a0mg\/kg, oral) and used for evaluation of immunomodulatory actions (In Vivo). We tested the antibacterial activity in vitro against numerous bacterial strains, including\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    (\n                    <jats:italic>E. coli)<\/jats:italic>\n                    . The phagocytic activity and survival of peritoneal macrophages were examined. Also, serum levels of immunoglobulin G (IgG), immunoglobulin M (IgM), and interferon-\u03b3 (INF-\u03b3) were estimated in\n                    <jats:italic>E. coli<\/jats:italic>\n                    -infected rats. We found that mirabegron exhibited significant antibacterial activity, particularly against\n                    <jats:italic>E. coli<\/jats:italic>\n                    . Phagocytic activity increased notably in vivo, indicating an improved innate immune response. Mirabegron also demonstrated a substantial rise in immunoglobulin and cytokine levels, enhancing acquired immunity. According to our findings, in vitro and in vivo tests of mirabegron revealed possible antibacterial activity as well as immunomodulatory properties. Mirabegron could alleviate symptomatic UTIs.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-23392-2","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:42:45Z","timestamp":1762504965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mirabegron exhibits antibacterial and Immunomodulatory activities demonstrated by in vitro and in vivo studies"],"prefix":"10.1038","volume":"15","author":[{"given":"Esraa A.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Abd-Eldayem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"23392_CR1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu, T. et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J. Pharmacol. Exp. Ther. 321, 642\u2013647 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"23392_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/nau.20420","volume":"26","author":"O Yamaguchi","year":"2007","unstructured":"Yamaguchi, O. & Chapple, C. R. Beta3-adrenoceptors in urinary bladder. Neurourol. Urodyn. 26, 752\u2013756 (2007).","journal-title":"Neurourol. Urodyn."},{"key":"23392_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar, V. et al. Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European\u2013Australian phase 3 trial. Eur. Urol. 63, 283\u2013295 (2013).","journal-title":"Eur. Urol."},{"key":"23392_CR4","doi-asserted-by":"crossref","unstructured":"Cui, Y., Zong, H., Yang, C., Yan, H. & Zhang, Y. The efficacy and safety of mirabegron in treating OAB: A systematic review and meta-analysis of phase III trials. Int. Urol. Nephrol. 46, 275\u2013284 (2013).","DOI":"10.1007\/s11255-013-0509-9"},{"key":"23392_CR5","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s11136-014-0904-4","volume":"24","author":"D Castro-Diaz","year":"2015","unstructured":"Castro-Diaz, D. et al. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: The results of post hoc correlation and responder analyses using pooled data from three randomized phase III trials. Qual. Life Res. 24, 1719 (2015).","journal-title":"Qual. Life Res."},{"key":"23392_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eururo.2014.06.052","volume":"67","author":"C Chapple","year":"2015","unstructured":"Chapple, C. et al. Efficacy of the \u03b23-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: A post hoc analysis of pooled data from three randomised phase 3 trials. Eur. Urol. 67, 11\u201314 (2015).","journal-title":"Eur. Urol."},{"key":"23392_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","volume":"33","author":"CR Chapple","year":"2014","unstructured":"Chapple, C. R., Cardozo, L., Nitti, V. W., Siddiqui, E. & Michel, M. C. Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. Neurourol. Urodyn. 33, 17\u201330 (2014).","journal-title":"Neurourol. Urodyn."},{"issue":"22","key":"23392_CR8","first-page":"1","volume":"2021 221","author":"GR Mullen","year":"2021","unstructured":"Mullen, G. R. & Kaplan, S. A. Efficacy and safety of mirabegron in men with overactive bladder symptoms and benign prostatic hyperplasia. Curr. Urol. Rep. 2021 221 (22), 1\u20137 (2021).","journal-title":"Curr. Urol. Rep."},{"key":"23392_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/psb.1089","volume":"24","author":"S Chaplin Bpharm","year":"2013","unstructured":"Chaplin Bpharm, S. & Chapple Bsc, C. Mirabegron: New treatment for OAB with fewer side-effects. Prescriber 24, 39\u201342 (2013).","journal-title":"Prescriber"},{"key":"23392_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jfma.2018.08.014","volume":"118","author":"CH Liao","year":"2019","unstructured":"Liao, C. H. & Kuo, H. C. Mirabegron escalation to 50\u00a0mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder. J. Formos. Med. Assoc. 118, 700\u2013706 (2019).","journal-title":"J. Formos. Med. Assoc."},{"key":"23392_CR11","doi-asserted-by":"crossref","unstructured":"Lee, J. et al. Role of cytochrome P450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a \u03b23-adrenoceptor agonist. Clin. Drug Investig. 33, 429\u2013440 (2013).","DOI":"10.1007\/s40261-013-0084-y"},{"key":"23392_CR12","doi-asserted-by":"crossref","unstructured":"Takusagawa, S. et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective \u03b23-adrenoceptor agonist. 42, 957\u2013967 (2012). https:\/\/doi.org\/10.3109\/00498254.2012.675095","DOI":"10.3109\/00498254.2012.675095"},{"key":"23392_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.111.043588","volume":"40","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa, S. et al. Metabolism and excretion of [14\u00a0C]Mirabegron (YM178), a potent and selective \u03b23-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab. Dispos. 40, 815\u2013824 (2012). Absorption.","journal-title":"Drug Metab. Dispos."},{"key":"23392_CR14","doi-asserted-by":"publisher","first-page":"e021889","DOI":"10.1136\/bmjopen-2018-021889","volume":"8","author":"G Yeowell","year":"2018","unstructured":"Yeowell, G. et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): A systematic literature review. BMJ Open. 8, e021889 (2018).","journal-title":"BMJ Open."},{"key":"23392_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner, D. J., Gomelsky, A., Souter, L. & Vasavada, S. P. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J. Urol. 202, 558\u2013563 (2019).","journal-title":"J. Urol."},{"key":"23392_CR16","first-page":"100020","volume":"5","author":"SR Kraus","year":"2023","unstructured":"Kraus, S. R. et al. Cost, resource utilization, and treatment-taking behaviors among patients with OAB initiating combination mirabegron and antimuscarinic therapy in the US. Cont. Rep. 5, 100020 (2023).","journal-title":"Cont. Rep."},{"key":"23392_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4103\/picr.picr_166_23","volume":"15","author":"MO Raj","year":"2024","unstructured":"Raj, M. O., Jose, J., Paul, F., Sreedharan, S. & Uthaman, N. Therapeutic effectiveness and adverse drug reactions of mirabegron versus Solifenacin in the treatment of overactive bladder syndrome. Perspect. Clin. Res. 15, 147\u2013151 (2024).","journal-title":"Perspect. Clin. Res."},{"key":"23392_CR18","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.18203\/2320-6012.ijrms20241963","volume":"12","author":"MS Agrawal","year":"2024","unstructured":"Agrawal, M. S., Pandey, S., Kumar, P., Sahu, V. & Patil, D. Role of mirabegron in the management of overactive bladder: A knowledge, attitude, and practice survey among Indian healthcare professionals. Int. J. Res. Med. Sci. 12, 2779\u20132785 (2024).","journal-title":"Int. J. Res. Med. Sci."},{"key":"23392_CR19","first-page":"1","volume":"2018 1911 19","author":"F Nik-Ahd","year":"2018","unstructured":"Nik-Ahd, F., Lenore Ackerman, A. & Anger, J. Recurrent urinary tract infections in females and the overlap with overactive bladder. Curr. Urol. Rep. 2018 1911 19, 1\u20135 (2018).","journal-title":"Curr. Urol. Rep."},{"key":"23392_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1067\/mda.2003.7","volume":"49","author":"B Foxman","year":"2003","unstructured":"Foxman, B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dis. Mon. 49, 53\u201370 (2003).","journal-title":"Dis. Mon"},{"key":"23392_CR21","doi-asserted-by":"crossref","unstructured":"Lyu, J. et al. Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial. Trials 20 (2019).","DOI":"10.1186\/s13063-019-3539-5"},{"key":"23392_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/2090598X.2019.1589932","volume":"17","author":"B Farhan","year":"2019","unstructured":"Farhan, B., Chang, H., Ahmed, A., Zaldivair, F. & Ghoniem, G. Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder. Arab. J. Urol. 17, 58 (2019).","journal-title":"Arab. J. Urol."},{"key":"23392_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5213\/inj.2040318.159","volume":"24","author":"JW Kim","year":"2020","unstructured":"Kim, J. W., Kim, S. J., Park, J. M., Na, Y. G. & Kim, K. H. Past, Present, and future in the study of neural control of the lower urinary tract. Int. Neurourol. J. 24, 191\u2013199 (2020).","journal-title":"Int. Neurourol. J."},{"key":"23392_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.euf.2018.06.011","volume":"5","author":"G Magistro","year":"2019","unstructured":"Magistro, G. & Stief, C. G. The urinary tract microbiome: The answer to all our open questions? Eur. Urol. Focus. 5, 36\u201338 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"23392_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.euf.2018.09.011","volume":"6","author":"T Antunes-Lopes","year":"2020","unstructured":"Antunes-Lopes, T. et al. The role of urinary microbiota in lower urinary tract dysfunction: A systematic review. Eur. Urol. Focus. 6, 361\u2013369 (2020).","journal-title":"Eur. Urol. Focus"},{"key":"23392_CR26","doi-asserted-by":"crossref","unstructured":"Kilis-Pstrusinska, K., Rogowski, A. & Bienkowski, P. Bacterial colonization as a possible source of overactive bladder symptoms in pediatric patients: A literature review. J Clin. Med 10 (2021).","DOI":"10.3390\/jcm10081645"},{"key":"23392_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/tcmj.tcmj_38_20","volume":"33","author":"QS Ke","year":"2021","unstructured":"Ke, Q. S., Lee, C. L. & Kuo, H. C. Recurrent urinary tract infection in women and overactive bladder\u2014Is there a relationship? Tzu-Chi Med. J. 33, 13 (2021).","journal-title":"Tzu-Chi Med. J."},{"key":"23392_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00467-019-04269-9","volume":"35","author":"C Ching","year":"2020","unstructured":"Ching, C., Schwartz, L., Spencer, J. D. & Becknell, B. Innate immunity and urinary tract infection. Pediatr. Nephrol. 35, 1183 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"23392_CR29","first-page":"25","volume":"12","author":"KM Liao","year":"2021","unstructured":"Liao, K. M., Lio, K. L., Chou, Y. J., Kuo, C. C. & Chen, C. Y. The association between urinary tract infection and overactive bladder treatment. Front. Pharmacol. 12, 25 (2021).","journal-title":"Front. Pharmacol."},{"key":"23392_CR30","doi-asserted-by":"crossref","unstructured":"Javan, B. et al. Differences in the urinary Microbiome of patients with overactive bladder syndrome with and without detrusor overactivity on urodynamic measurements. Life (Basel Switzerland) 13 (2023).","DOI":"10.3390\/life13051199"},{"key":"23392_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/NAU.25550","author":"N Hashemi","year":"2024","unstructured":"Hashemi, N. et al. A systematic and comprehensive review of the role of microbiota in urinary chronic pelvic pain syndrome. Neurourol. Urodyn. https:\/\/doi.org\/10.1002\/NAU.25550 (2024).","journal-title":"Neurourol. Urodyn."},{"key":"23392_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejogrb.2016.03.024","volume":"201","author":"AA Balachandran","year":"2016","unstructured":"Balachandran, A. A., Wildman, S. S., Strutt, M. & Duckett, J. Is chronic urinary infection a cause of overactive bladder? Eur. J. Obstet. Gynecol. Reprod. Biol. 201, 108\u2013112 (2016).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"23392_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2022.886782","volume":"13","author":"KJ Mansfield","year":"2022","unstructured":"Mansfield, K. J., Chen, Z., Moore, K. H. & Grundy, L. Urinary tract infection in overactive bladder: An update on pathophysiological mechanisms. Front. Physiol. 13, 1\u201312 (2022).","journal-title":"Front. Physiol."},{"key":"23392_CR34","doi-asserted-by":"crossref","unstructured":"Ognenovska, S., Chen, Z., Mukerjee, C., Moore, K. H. & Mansfield, K. J. Bacterial colonization of bladder urothelial cells in women with refractory detrusor overactivity: The effects of antibiotic therapy. Pathog Dis 79, (2021).","DOI":"10.1093\/femspd\/ftab031"},{"key":"23392_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fimmu.2017.00336","volume":"8","author":"R Weissert","year":"2017","unstructured":"Weissert, R. Adaptive immunity is the key to the understanding of autoimmune and paraneoplastic inflammatory central nervous system disorders. Front. Immunol. 8, 23 (2017).","journal-title":"Front. Immunol."},{"key":"23392_CR36","doi-asserted-by":"crossref","unstructured":"Bellinger, D. L. & Lorton, D. Sympathetic nerve hyperactivity in the spleen: Causal for Nonpathogenic-Driven chronic Immune-Mediated inflammatory diseases (IMIDs)? Int. J. Mol. Sci. 19, (2018).","DOI":"10.3390\/ijms19041188"},{"key":"23392_CR37","first-page":"175628721882408","volume":"11","author":"JAO Martell","year":"2019","unstructured":"Martell, J. A. O., Naber, K. G., Haddad, J. M., Saucedo, J. T. & Burgos, J. A. D. Prevention of recurrent urinary tract infections: Bridging the Gapbetween clinical practice and guidelines in Latin America. Ther. Adv. Urol. 11, 175628721882408 (2019).","journal-title":"Ther. Adv. Urol."},{"key":"23392_CR38","first-page":"55","volume":"451 45","author":"F Marino","year":"2011","unstructured":"Marino, F. & Cosentino, M. Adrenergic modulation of immune cells: An update. Amin Acids 2011. 45, 55\u201371 (2011).","journal-title":"Amin Acids 2011 451"},{"key":"23392_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF03179914","volume":"59","author":"O Lamas","year":"2003","unstructured":"Lamas, O., Martin\u00e9z, J. A. & Marti, A. Effects of a beta3-adrenergic agonist on the immune response in diet-induced (cafeteria) obese animals. J. Physiol. Biochem. 59, 183\u2013192 (2003).","journal-title":"J. Physiol. Biochem."},{"key":"23392_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fphar.2015.00171","volume":"6","author":"A Scanzano","year":"2015","unstructured":"Scanzano, A. & Cosentino, M. Adrenergic regulation of innate immunity: A review. Front. Pharmacol. 6, 171 (2015).","journal-title":"Front. Pharmacol."},{"key":"23392_CR41","first-page":"159","volume":"14","author":"A Pasha","year":"2024","unstructured":"Pasha, A., Tondo, A., Favre, C. & Calvani, M. Inside the biology of the \u03b23-Adrenoceptor. Biomol. 2024. 14, 159 (2024).","journal-title":"Biomol. 2024"},{"key":"23392_CR42","doi-asserted-by":"crossref","unstructured":"Mueller, J. H. & Hinton, J. A. Protein-free medium for primary isolation of the gonococcus and meningococcus 48, 330\u2013333. https:\/\/doi.org\/10.3181\/00379727- (2016)","DOI":"10.3181\/00379727-48-13311"},{"key":"23392_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0305-4179(78)80006-0","volume":"4","author":"P Nathan","year":"1978","unstructured":"Nathan, P., Law, E. J., Murphy, D. F. & MacMillan, B. G. A laboratory method for selection of topical antimicrobial agents to treat infected burn wounds. Burns 4, 177\u2013187 (1978).","journal-title":"Burns"},{"key":"23392_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpha.2015.11.005","volume":"6","author":"M Balouiri","year":"2016","unstructured":"Balouiri, M., Sadiki, M. & Ibnsouda, S. K. Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm. Anal. 6, 71 (2016).","journal-title":"J. Pharm. Anal."},{"key":"23392_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jgar.2016.12.018","volume":"9","author":"P Thakur","year":"2017","unstructured":"Thakur, P., Chawla, R., Narula, A. & Sharma, R. K. Protective effect of berberis aristata against peritonitis induced by carbapenem-resistant Escherichia coli in a mammalian model. J. Glob Antimicrob. Resist. 9, 21\u201329 (2017).","journal-title":"J. Glob Antimicrob. Resist."},{"key":"23392_CR46","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.eururo.2013.06.043","volume":"64","author":"N Sawada","year":"2013","unstructured":"Sawada, N. et al. Protective effect of a \u03b23-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur. Urol. 64, 664\u2013671 (2013).","journal-title":"Eur. Urol."},{"key":"23392_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cellbi.2004.04.006","volume":"28","author":"V Nimet Izg\u00fct-Uysal","year":"2004","unstructured":"Nimet Izg\u00fct-Uysal, V., Tan, R., B\u00fclb\u00fcl, M. & Derin, N. Effect of stress-induced lipid peroxidation on functions of rat peritoneal macrophages. Cell. Biol. Int. 28, 517\u2013521 (2004).","journal-title":"Cell. Biol. Int."},{"key":"23392_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cellimm.2011.06.005","volume":"271","author":"VN Izg\u00fct-Uysal","year":"2011","unstructured":"Izg\u00fct-Uysal, V. N., Gemici, B. & Tan, R. Effect of orexin-A on phagocytic activity of peritoneal macrophage in starved rats. Cell. Immunol. 271, 85\u201388 (2011).","journal-title":"Cell. Immunol."},{"key":"23392_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams, P. et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the international continence society. Urology 61, 37\u201349 (2003).","journal-title":"Urology"},{"key":"23392_CR50","first-page":"100059","volume":"11","author":"CG Jensen","year":"2024","unstructured":"Jensen, C. G., Secher, C., Hvid, N. K. & Lund, L. The history of the pharmacologic treatment of urgency incontinence. Cont. Rep. 11, 100059 (2024).","journal-title":"Cont. Rep."},{"key":"23392_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756287212457114","volume":"4","author":"E Sacco","year":"2012","unstructured":"Sacco, E. & Bientinesi, R. Mirabegron: A review of recent data and its prospects in the management of overactive bladder. Ther. Adv. Urol. 4, 315\u2013324 (2012).","journal-title":"Ther. Adv. Urol."},{"key":"23392_CR52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/DDDT.S101630","volume":"11","author":"A Sharaf","year":"2017","unstructured":"Sharaf, A. & Hashim, H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des. Devel Ther. 11, 463 (2017).","journal-title":"Drug Des. Devel Ther."},{"key":"23392_CR53","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/bph.14658","volume":"176","author":"Y Igawa","year":"2019","unstructured":"Igawa, Y., Aizawa, N. & Michel, M. C. \u03b23-Adrenoceptors in the normal and diseased urinary bladder\u2014What are the open questions? Br. J. Pharmacol. 176, 2525 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"23392_CR54","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2147\/IJWH.S372597","volume":"14","author":"M O\u2019kane","year":"2022","unstructured":"O\u2019kane, M., Robinson, D., Cardozo, L., Wagg, A. & Abrams, P. Mirabegron in the management of overactive bladder syndrome. Int. J. Womens Health. 14, 1337\u20131350 (2022).","journal-title":"Int. J. Womens Health"},{"key":"23392_CR55","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","volume":"6","author":"H Kakizaki","year":"2020","unstructured":"Kakizaki, H. et al. Mirabegron Add-on therapy to Tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A randomized, placebo-controlled study (MATCH). Eur. Urol. Focus. 6, 729\u2013737 (2020).","journal-title":"Eur. Urol. Focus"},{"key":"23392_CR56","doi-asserted-by":"crossref","unstructured":"Matsuo, T. et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with \u03b11-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urol. 16, (2016).","DOI":"10.1186\/s12894-016-0165-3"},{"key":"23392_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/J.EUF.2024.09.012","author":"A Dey","year":"2024","unstructured":"Dey, A. et al. Mirabegron versus placebo and other therapeutic modalities in the treatment of patients with overactive bladder Syndrome-A systematic review. Eur. Urol. Focus. https:\/\/doi.org\/10.1016\/J.EUF.2024.09.012 (2024).","journal-title":"Eur. Urol. Focus"},{"key":"23392_CR58","doi-asserted-by":"crossref","unstructured":"Fogaing, C., Mossa, A. H. & Campeau, L. Are beta 3 adrenergic agonists now the preferred Pharmacologic management of overactive bladder? Curr Urol. Rep 21 (2020).","DOI":"10.1007\/s11934-020-01003-z"},{"key":"23392_CR59","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","volume":"63","author":"CR Chapple","year":"2013","unstructured":"Chapple, C. R. et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder. Eur. Urol. 63, 296\u2013305 (2013).","journal-title":"Eur. Urol."},{"key":"23392_CR60","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhang, A., Ye, M. & Zhang, C. Examining the safety of mirabegron: An analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Front Pharmacol 15 (2024).","DOI":"10.3389\/fphar.2024.1376535"},{"key":"23392_CR61","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.bbi.2018.06.017","volume":"73","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Sustained stimulation of \u03b22- and \u03b23-adrenergic receptors leads to persistent functional pain and neuroinflammation. Brain Behav. Immun. 73, 520\u2013532 (2018).","journal-title":"Brain Behav. Immun."},{"key":"23392_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1165\/rcmb.2008-0091TR","volume":"39","author":"CH Serezani","year":"2008","unstructured":"Serezani, C. H., Ballinger, M. N., Aronoff, D. M. & Peters-Golden, M. Translational review cyclic AMP master regulator of innate immune cell function. Am. J. Respir Cell. Mol. Biol. 39, 27\u2013132 (2008).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"23392_CR63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1006\/bbrc.1995.1099","volume":"206","author":"WS Koh","year":"1995","unstructured":"Koh, W. S., Yang, K. H. & Kaminski, N. E. Cyclic AMP is an essential factor in immune responses. Biochem. Biophys. Res. Commun. 206, 703\u2013709 (1995).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"23392_CR64","first-page":"1","volume":"2507","author":"SXY Shi","year":"2020","unstructured":"Shi, S. X. Y. Focal and systemic immune responses following intracerebral hemorrhage. ProQuest LLC. 2507, 1\u20139 (2020).","journal-title":"ProQuest LLC"},{"key":"23392_CR65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1054\/mehy.2000.1127","volume":"56","author":"B Xu","year":"2001","unstructured":"Xu, B. The importance of beta-adrenergic receptors in immune regulation: A link between neuroendocrine and immune system. Med. Hypotheses. 56, 273\u2013276 (2001).","journal-title":"Med. Hypotheses"},{"key":"23392_CR66","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41417-023-00599-x","volume":"30","author":"G Bruno","year":"2023","unstructured":"Bruno, G. et al. \u03b23-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN-\u03b3-dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma. Cancer Gene Ther. 30, 890\u2013904 (2023).","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"23392_CR67","first-page":"380","volume":"2","author":"J Ma","year":"2022","unstructured":"Ma, J. et al. Mirabegron and physical exercise is a potential strategical for BAT activation in obesity. Obesities 2022. 2 (2), 380\u2013388 (2022).","journal-title":"Obesities 2022"},{"key":"23392_CR68","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.neuroscience.2008.07.011","volume":"156","author":"Y Claustre","year":"2008","unstructured":"Claustre, Y. et al. Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant\/anxiolytic-like profile. Neuroscience 156, 353\u2013364 (2008).","journal-title":"Neuroscience"},{"key":"23392_CR69","doi-asserted-by":"publisher","first-page":"R781","DOI":"10.1152\/ajpregu.00358.2019","volume":"318","author":"I Mishra","year":"2020","unstructured":"Mishra, I. et al. Chemical sympathectomy reduces peripheral inflammatory responses to acute and chronic sleep fragmentation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 318, R781\u2013R789 (2020).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"23392_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0008-8749(88)90318-8","volume":"114","author":"BA Fuchs","year":"1988","unstructured":"Fuchs, B. A., Albright, J. W. & Albright, J. F. Beta-adrenergic receptors on murine lymphocytes: Density varies with cell maturity and lymphocyte subtype and is decreased after antigen administration. Cell. Immunol. 114, 231\u2013245 (1988).","journal-title":"Cell. Immunol."},{"key":"23392_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.102.035048","volume":"304","author":"B Liu","year":"2003","unstructured":"Liu, B. & Hong, J. S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1\u20137 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"23392_CR72","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bbi.2014.10.007","volume":"45","author":"K Kolmus","year":"2015","unstructured":"Kolmus, K., Tavernier, J. & Gerlo, S. \u03b22-Adrenergic receptors in immunity and inflammation: Stressing NF-\u03baB. Brain Behav. Immun. 45, 297\u2013310 (2015).","journal-title":"Brain Behav. Immun."},{"key":"23392_CR73","doi-asserted-by":"crossref","unstructured":"Wheeler, N. D., Ensminger, D. C., Rowe, M. M., Wriedt, Z. S. & Ashley, N. T. Alpha- and beta- adrenergic receptors regulate inflammatory responses to acute and chronic sleep fragmentation in mice. PeerJ 9 (2021).","DOI":"10.7717\/peerj.11616"},{"key":"23392_CR74","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.bbamcr.2017.07.003","volume":"1864","author":"T Hadi","year":"2017","unstructured":"Hadi, T. et al. Beta3 adrenergic receptor stimulation in human macrophages inhibits nadphoxidase activity and induces catalase expression via PPAR\u03b3 activation. Biochim. Biophys. Acta Mol. Cell. Res. 1864, 1769\u20131784 (2017).","journal-title":"Biochim. Biophys. Acta - Mol. Cell. Res."},{"key":"23392_CR75","doi-asserted-by":"publisher","first-page":"112","DOI":"10.53350\/pjmhs22169112","volume":"16","author":"AH Arain","year":"2022","unstructured":"Arain, A. H. et al. Effect of mirabegron to reduce lower urinary tract symptoms in prostatitis. Pakistan J. Med. Health Sci. 16, 112\u2013114 (2022).","journal-title":"Pakistan J. Med. Heal Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23392-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:03:08Z","timestamp":1762509788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23392-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23392"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23392-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study\u2019s protocol was approved by the Research Ethical Committee of the Faculty of Medicine at Assiut University (IRB. No. 04-2024-300424).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"39010"}}